{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:41:18Z","timestamp":1792788078836,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82300132"],"award-info":[{"award-number":["82300132"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82350104"],"award-info":[{"award-number":["82350104"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82470120"],"award-info":[{"award-number":["82470120"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82450001"],"award-info":[{"award-number":["82450001"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFA1100800"],"award-info":[{"award-number":["2021YFA1100800"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2024YFA1108302"],"award-info":[{"award-number":["2024YFA1108302"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2023ZD0501200"],"award-info":[{"award-number":["2023ZD0501200"]}]},{"name":"R&D program of Beijing Escure Biotechnology Co., Ltd","award":["E441O71131"],"award-info":[{"award-number":["E441O71131"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-025-01712-3","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T12:04:44Z","timestamp":1747656284000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Engineered CRO-CD7 CAR-NK cells derived from pluripotent stem cells avoid fratricide and efficiently suppress human T-cell malignancies"],"prefix":"10.1186","volume":"18","author":[{"given":"Yunqing","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyun","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangxiao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiujuan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dehao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengxiang","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qitong","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leqiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoqin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanmeng","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyuan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengcheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiacheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingliao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aibin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongjie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"key":"1712_CR1","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1182\/blood-2014-10-551895","volume":"126","author":"MR Litzow","year":"2015","unstructured":"Litzow MR, Ferrando AA. How I treat T-cell acute lymphoblastic leukemia in adults. Blood. 2015;126:833\u201341.","journal-title":"Blood"},{"key":"1712_CR2","doi-asserted-by":"publisher","first-page":"5136","DOI":"10.1182\/blood-2009-08-231217","volume":"114","author":"DI Marks","year":"2009","unstructured":"Marks DI, et al. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII\/ECOG 2993). Blood. 2009;114:5136\u201345.","journal-title":"Blood"},{"key":"1712_CR3","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1182\/blood-2016-07-692608","volume":"129","author":"DI Marks","year":"2017","unstructured":"Marks DI, Rowntree C. Management of adults with T-cell lymphoblastic leukemia. Blood. 2017;129:1134\u201342.","journal-title":"Blood"},{"key":"1712_CR4","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park JH, et al. Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. N Engl J Med. 2018;378:449\u201359.","journal-title":"N Engl J Med"},{"key":"1712_CR5","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje N, et al. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2019;380:1726\u201337.","journal-title":"N Engl J Med"},{"key":"1712_CR6","doi-asserted-by":"publisher","first-page":"517","DOI":"10.4049\/jimmunol.152.2.517","volume":"152","author":"H Rabinowich","year":"1994","unstructured":"Rabinowich H, Pricop L, Herberman RB, Whiteside TL. Expression and function of CD7 molecule on human natural killer cells. J Immunol. 1994;152:517\u201326.","journal-title":"J Immunol"},{"key":"1712_CR7","doi-asserted-by":"publisher","first-page":"3632","DOI":"10.4049\/jimmunol.143.11.3632","volume":"143","author":"RE Ware","year":"1989","unstructured":"Ware RE, Scearce RM, Dietz MA, Starmer CF, Palker TJ, Haynes BF. Characterization of the surface topography and putative tertiary structure of the human CD7 molecule. J Immunol. 1989;143:3632\u201340.","journal-title":"J Immunol"},{"key":"1712_CR8","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1182\/blood.V77.7.1546.1546","volume":"77","author":"D Campana","year":"1991","unstructured":"Campana D, van Dongen JJ, Mehta A, Coustan-Smith E, Wolvers-Tettero IL, Ganeshaguru K, Janossy G. Stages of T-cell receptor protein expression in T-cell acute lymphoblastic leukemia. Blood. 1991;77:1546\u201354.","journal-title":"Blood"},{"key":"1712_CR9","doi-asserted-by":"crossref","unstructured":"Bayon-Calderon F, Toribio ML, Gonzalez-Garcia S. Facts and Challenges in Immunotherapy for T-Cell Acute Lymphoblastic Leukemia. Int J Mol Sci. 2020;21:7685.","DOI":"10.3390\/ijms21207685"},{"key":"1712_CR10","first-page":"3340","volume":"39","author":"J Pan","year":"2021","unstructured":"Pan J, et al. Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human. Phase I Trial J Clin Oncol. 2021;39:3340\u201351.","journal-title":"Phase I Trial J Clin Oncol"},{"key":"1712_CR11","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/s41571-021-00556-3","volume":"18","author":"DT Teachey","year":"2021","unstructured":"Teachey DT, Hunger SP. Anti-CD7 CAR T cells for T-ALL: impressive early-stage efficacy. Nat Rev Clin Oncol. 2021;18:677\u20138.","journal-title":"Nat Rev Clin Oncol"},{"key":"1712_CR12","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","volume":"130","author":"D Gomes-Silva","year":"2017","unstructured":"Gomes-Silva D, Srinivasan M, Sharma S, Lee CM, Wagner DL, Davis TH, Rouce RH, Bao G, Brenner MK, Mamonkin M. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood. 2017;130:285\u201396.","journal-title":"Blood"},{"key":"1712_CR13","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.1038\/s41375-021-01282-6","volume":"35","author":"C Georgiadis","year":"2021","unstructured":"Georgiadis C, Rasaiyaah J, Gkazi SA, Preece R, Etuk A, Christi A, Qasim W. Base-edited CAR T cells for combinational therapy against T cell malignancies. Leukemia. 2021;35:3466\u201381.","journal-title":"Leukemia"},{"key":"1712_CR14","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ymthe.2018.10.001","volume":"27","author":"D Gomes-Silva","year":"2019","unstructured":"Gomes-Silva D, et al. CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia. Mol Ther. 2019;27:272\u201380.","journal-title":"Mol Ther"},{"key":"1712_CR15","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1038\/s41375-023-01948-3","volume":"37","author":"J Jiang","year":"2023","unstructured":"Jiang J, Chen J, Liao C, Duan Y, Wang Y, Shang K, Huang Y, Tang Y, Gao X, Gu Y, Sun J. Inserting EF1alpha-driven CD7-specific CAR at CD7 locus reduces fratricide and enhances tumor rejection. Leukemia. 2023;37:1660\u201370.","journal-title":"Leukemia"},{"key":"1712_CR16","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1038\/s41375-023-02018-4","volume":"37","author":"S Li","year":"2023","unstructured":"Li S, et al. CD7 targeted \u201coff-the-shelf\u201d CAR-T demonstrates robust in vivo expansion and high efficacy in the treatment of patients with relapsed and refractory T cell malignancies. Leukemia. 2023;37:2176\u201386.","journal-title":"Leukemia"},{"key":"1712_CR17","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1182\/bloodadvances.2017009928","volume":"1","author":"YT Png","year":"2017","unstructured":"Png YT, Vinanica N, Kamiya T, Shimasaki N, Coustan-Smith E, Campana D. Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies. Blood Adv. 2017;1:2348\u201360.","journal-title":"Blood Adv"},{"key":"1712_CR18","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1038\/s41590-023-01659-y","volume":"24","author":"OK Dagher","year":"2023","unstructured":"Dagher OK, Posey AD Jr. Forks in the road for CAR T and CAR NK cell cancer therapies. Nat Immunol. 2023;24:1994\u20132007.","journal-title":"Nat Immunol"},{"key":"1712_CR19","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s12265-008-9032-2","volume":"1","author":"JJ Pappas","year":"2008","unstructured":"Pappas JJ, Yang PC. Human ESC vs iPSC-pros and cons. J Cardiovasc Transl Res. 2008;1:96\u20139.","journal-title":"J Cardiovasc Transl Res."},{"key":"1712_CR20","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1182\/blood.2021015184","volume":"140","author":"F Cichocki","year":"2022","unstructured":"Cichocki F, et al. Dual antigen-targeted off-the-shelf NK cells show durable response and prevent antigen escape in lymphoma and leukemia. Blood. 2022;140:2451\u201362.","journal-title":"Blood"},{"issue":"181\u2013192","key":"1712_CR21","volume":"23","author":"Y Li","year":"2018","unstructured":"Li Y, Hermanson DL, Moriarity BS, Kaufman DS. Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity. Cell Stem Cell. 2018;23(181\u2013192): e185.","journal-title":"Cell Stem Cell"},{"key":"1712_CR22","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13727","volume":"57","author":"Y Liu","year":"2024","unstructured":"Liu Y, et al. Mesothelin CAR-engineered NK cells derived from human embryonic stem cells suppress the progression of human ovarian cancer in animals. Cell Prolif. 2024;57: e13727.","journal-title":"Cell Prolif"},{"key":"1712_CR23","doi-asserted-by":"publisher","first-page":"1504459","DOI":"10.3389\/fimmu.2024.1504459","volume":"15","author":"Q Zhang","year":"2024","unstructured":"Zhang Q, et al. Hypoimmunogenic CD19 CAR-NK cells derived from embryonic stem cells suppress the progression of human B-cell malignancies in xenograft animals. Front Immunol. 2024;15:1504459.","journal-title":"Front Immunol"},{"key":"1712_CR24","doi-asserted-by":"crossref","unstructured":"Sabbah M, Jondreville L, Lacan C, Norol F, Vieillard V, Roos-Weil D, Nguyen S. CAR-NK Cells: A Chimeric Hope or a Promising Therapy? Cancers (Basel). 2022;14:3839.","DOI":"10.3390\/cancers14153839"},{"key":"1712_CR25","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1182\/blood-2002-10-3293","volume":"102","author":"K Beider","year":"2003","unstructured":"Beider K, et al. Involvement of CXCR4 and IL-2 in the homing and retention of human NK and NK T cells to the bone marrow and spleen of NOD\/SCID mice. Blood. 2003;102:1951\u20138.","journal-title":"Blood"},{"key":"1712_CR26","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.3389\/fimmu.2019.01262","volume":"10","author":"E Levy","year":"2019","unstructured":"Levy E, Reger R, Segerberg F, Lambert M, Leijonhufvud C, Baumer Y, Carlsten M, Childs R. Enhanced Bone Marrow Homing of Natural Killer Cells Following mRNA Transfection With Gain-of-Function Variant CXCR4(R334X). Front Immunol. 2019;10:1262.","journal-title":"Front Immunol"},{"key":"1712_CR27","doi-asserted-by":"publisher","first-page":"1383136","DOI":"10.3389\/fimmu.2024.1383136","volume":"15","author":"MW Moles","year":"2024","unstructured":"Moles MW, et al. CXCR4 has a dual role in improving the efficacy of BCMA-redirected CAR-NK cells in multiple myeloma. Front Immunol. 2024;15:1383136.","journal-title":"Front Immunol"},{"key":"1712_CR28","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/CJI.0000000000000082","volume":"38","author":"N Muller","year":"2015","unstructured":"Muller N, Michen S, Tietze S, Topfer K, Schulte A, Lamszus K, Schmitz M, Schackert G, Pastan I, Temme A. Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12\/SDF-1alpha-secreting Glioblastoma. J Immunother. 2015;38:197\u2013210.","journal-title":"J Immunother"},{"key":"1712_CR29","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41417-021-00365-x","volume":"29","author":"YY Ng","year":"2022","unstructured":"Ng YY, Du Z, Zhang X, Chng WJ, Wang S. CXCR4 and anti-BCMA CAR co-modified natural killer cells suppress multiple myeloma progression in a xenograft mouse model. Cancer Gene Ther. 2022;29:475\u201383.","journal-title":"Cancer Gene Ther"},{"key":"1712_CR30","doi-asserted-by":"publisher","DOI":"10.1101\/2025.01.07.631650","author":"Z Wang","year":"2025","unstructured":"Wang Z, et al. Pluripotent stem cell-derived NK progenitor cell therapy prevents tumour occurrence and eradicates minimal residual disease. 2025. https:\/\/doi.org\/10.1101\/2025.01.07.631650.","journal-title":"Pluripotent stem cell-derived NK progenitor cell therapy prevents tumour occurrence and eradicates minimal residual disease"},{"key":"1712_CR31","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1046\/j.1365-2141.1996.d01-1900.x","volume":"95","author":"W Baum","year":"1996","unstructured":"Baum W, Steininger H, Bair HJ, Becker W, Hansen-Hagge TE, Kressel M, Kremmer E, Kalden JR, Gramatzki M. Therapy with CD7 monoclonal antibody TH-69 is highly effective for xenografted human T-cell ALL. Br J Haematol. 1996;95:327\u201338.","journal-title":"Br J Haematol"},{"key":"1712_CR32","doi-asserted-by":"publisher","first-page":"6733","DOI":"10.1073\/pnas.92.15.6733","volume":"92","author":"I Riviere","year":"1995","unstructured":"Riviere I, Brose K, Mulligan RC. Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc Natl Acad Sci U S A. 1995;92:6733\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1712_CR33","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13683","volume":"57","author":"Y Wang","year":"2024","unstructured":"Wang Y, et al. Comparison of seven CD19 CAR designs in engineering NK cells for enhancing anti-tumour activity. Cell Prolif. 2024;57: e13683.","journal-title":"Cell Prolif"},{"key":"1712_CR34","volume":"3","author":"Y Chen","year":"2022","unstructured":"Chen Y, Hu Y, Wang X, Luo S, Yang N, Chen Y, Li Z, Zhou Q, Li W. Synergistic engineering of CRISPR-Cas nucleases enables robust mammalian genome editing. Innovation (Camb). 2022;3: 100264.","journal-title":"Innovation (Camb)"},{"key":"1712_CR35","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41421-022-00467-2","volume":"8","author":"D Huang","year":"2022","unstructured":"Huang D, et al. Lateral plate mesoderm cell-based organoid system for NK cell regeneration from human pluripotent stem cells. Cell Discov. 2022;8:121.","journal-title":"Cell Discov"},{"key":"1712_CR36","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/978-1-60761-362-6_2","volume":"612","author":"F Cichocki","year":"2010","unstructured":"Cichocki F, Miller JS. In vitro development of human Killer-Immunoglobulin Receptor-positive NK cells. Methods Mol Biol. 2010;612:15\u201326.","journal-title":"Methods Mol Biol"},{"key":"1712_CR37","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s12967-021-02925-z","volume":"19","author":"R Haderbache","year":"2021","unstructured":"Haderbache R, et al. Droplet digital PCR allows vector copy number assessment and monitoring of experimental CAR T cells in murine xenograft models or approved CD19 CAR T cell-treated patients. J Transl Med. 2021;19:265.","journal-title":"J Transl Med"},{"key":"1712_CR38","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1182\/blood-2010-04-277897","volume":"117","author":"M Noda","year":"2011","unstructured":"Noda M, Omatsu Y, Sugiyama T, Oishi S, Fujii N, Nagasawa T. CXCL12-CXCR4 chemokine signaling is essential for NK-cell development in adult mice. Blood. 2011;117:451\u20138.","journal-title":"Blood"},{"key":"1712_CR39","doi-asserted-by":"publisher","first-page":"1170968","DOI":"10.3389\/fimmu.2023.1170968","volume":"14","author":"J Liu","year":"2023","unstructured":"Liu J, Zhang Y, Guo R, Zhao Y, Sun R, Guo S, Lu W, Zhao M. Targeted CD7 CAR T-cells for treatment of T-Lymphocyte leukemia and lymphoma and acute myeloid leukemia: recent advances. Front Immunol. 2023;14:1170968.","journal-title":"Front Immunol"},{"key":"1712_CR40","first-page":"64","volume":"9","author":"F You","year":"2019","unstructured":"You F, Wang Y, Jiang L, Zhu X, Chen D, Yuan L, An G, Meng H, Yang L. A novel CD7 chimeric antigen receptor-modified NK-92MI cell line targeting T-cell acute lymphoblastic leukemia. Am J Cancer Res. 2019;9:64\u201378.","journal-title":"Am J Cancer Res"},{"key":"1712_CR41","doi-asserted-by":"publisher","unstructured":"Lei W, et al. Safety and feasibility of 4\u20131BB co-stimulated CD19-specific CAR-NK cell therapy in refractory\/relapsed large B cell lymphoma: a phase 1 trial. Nat Cancer. 2025. https:\/\/doi.org\/10.1038\/s43018-025-00940-3.","DOI":"10.1038\/s43018-025-00940-3"},{"key":"1712_CR42","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/S0140-6736(24)02524-8","volume":"405","author":"RM Shapiro","year":"2025","unstructured":"Shapiro RM, Romee R. iPSC-derived CD19 CAR NK cells for relapsed or refractory lymphoma. Lancet. 2025;405:98\u20139.","journal-title":"Lancet"},{"key":"1712_CR43","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s12885-023-11806-1","volume":"24","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Zhang C, He M, Xing W, Hou R, Zhang H. Co-expression of IL-21-Enhanced NKG2D CAR-NK cell therapy for lung cancer. BMC Cancer. 2024;24:119.","journal-title":"BMC Cancer"},{"key":"1712_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115123","volume":"165","author":"X Lin","year":"2023","unstructured":"Lin X, Sun Y, Dong X, Liu Z, Sugimura R, Xie G. IPSC-derived CAR-NK cells for cancer immunotherapy. Biomed Pharmacother. 2023;165: 115123.","journal-title":"Biomed Pharmacother"},{"key":"1712_CR45","doi-asserted-by":"crossref","unstructured":"Snyder KM, et al. iPSC-derived natural killer cells expressing the FcgammaR fusion CD64\/16A can be armed with antibodies for multitumor antigen targeting. J Immunother Cancer. 2023;11:e007280.","DOI":"10.1136\/jitc-2023-007280"},{"key":"1712_CR46","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1038\/s41467-024-46343-3","volume":"15","author":"KB Lupo","year":"2024","unstructured":"Lupo KB, Yao X, Borde S, Wang J, Torregrosa-Allen S, Elzey BD, Utturkar S, Lanman NA, McIntosh M, Matosevic S. synNotch-programmed iPSC-derived NK cells usurp TIGIT and CD73 activities for glioblastoma therapy. Nat Commun. 2024;15:1909.","journal-title":"Nat Commun"},{"issue":"1327\u20131343","key":"1712_CR47","volume":"31","author":"JL Thangaraj","year":"2024","unstructured":"Thangaraj JL, Coffey M, Lopez E, Kaufman DS. Disruption of TGF-beta signaling pathway is required to mediate effective killing of hepatocellular carcinoma by human iPSC-derived NK cells. Cell Stem Cell. 2024;31(1327\u20131343): e1325.","journal-title":"Cell Stem Cell"},{"key":"1712_CR48","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0140-6736(24)02462-0","volume":"405","author":"A Ghobadi","year":"2025","unstructured":"Ghobadi A, et al. Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial. Lancet. 2025;405:127\u201336.","journal-title":"Lancet"},{"key":"1712_CR49","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1038\/s41422-022-00721-y","volume":"32","author":"Y Hu","year":"2022","unstructured":"Hu Y, et al. Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed\/refractory CD7-positive hematological malignancies: a phase I clinical study. Cell Res. 2022;32:995\u20131007.","journal-title":"Cell Res"},{"key":"1712_CR50","first-page":"321","volume":"140","author":"P Lu","year":"2022","unstructured":"Lu P, Liu Y, Yang J, Zhang X, Yang X, Wang H, Wang L, Wang Q, Jin D, Li J, Huang X. Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL\/LBL: first-in-human phase 1 clinical trial. Blood. 2022;140:321\u201334.","journal-title":"Blood"},{"key":"1712_CR51","doi-asserted-by":"publisher","first-page":"101889","DOI":"10.1016\/j.xcrm.2024.101889","volume":"6","author":"L Wang","year":"2024","unstructured":"Wang L, et al. CD70-targeted iPSC-derived CAR-NK cells display potent function against tumors and alloreactive T cells. Cell Rep Med. 2024;6:101889.","journal-title":"Cell Rep Med."},{"key":"1712_CR52","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41586-021-04248-x","volume":"602","author":"SV Gearty","year":"2022","unstructured":"Gearty SV, et al. An autoimmune stem-like CD8 T cell population drives type 1 diabetes. Nature. 2022;602:156\u201361.","journal-title":"Nature"},{"key":"1712_CR53","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202300738","volume":"10","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Zhang J, Cheng X, Huang W, Shen S, Wu S, Huang Y, Nie G, Wang H, Qiu W. Targeting L-Selectin Lymphocytes to Deliver Immunosuppressive Drug in Lymph Nodes for Durable Multiple Sclerosis Treatment. Adv Sci (Weinh). 2023;10: e2300738.","journal-title":"Adv Sci (Weinh)"},{"key":"1712_CR54","doi-asserted-by":"crossref","unstructured":"Kim MY, Cooper ML, Jacobs MT, Ritchey JK, Hollaway J, Fehniger TA, DiPersio JF. CD7-deleted hematopoietic stem cells can restore immunity after CAR T cell therapy. JCI Insight. 2021;6:e149819.","DOI":"10.1172\/jci.insight.149819"},{"key":"1712_CR55","doi-asserted-by":"crossref","unstructured":"Polonen P, Mullighan CG, Teachey DT. Classification and risk stratification in T-lineage acute lymphoblastic leukemia. Blood. 2024;145:1464\u201374.","DOI":"10.1182\/blood.2023022920"},{"key":"1712_CR56","doi-asserted-by":"crossref","unstructured":"Millar HJ, et al. CXCR4 transgene improves in vivo migration and efficacy of engineered iPSC-derived natural killer cells. Cancer Research. 2024;84:6802.","DOI":"10.1158\/1538-7445.AM2024-6802"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01712-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-025-01712-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01712-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T13:03:14Z","timestamp":1747659794000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-025-01712-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1712"],"URL":"https:\/\/doi.org\/10.1186\/s13045-025-01712-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.01.23.634617","asserted-by":"object"}]},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,19]]},"assertion":[{"value":"23 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Experiments and handling of mice were conducted under the Institutional Animal Care and Use Committee of the Institute of Zoology, Chinese Academy of Sciences. The studies involving humans were approved by the Biomedical Research Ethics Committee of the Institute of Zoology, Chinese Academy of Sciences. The use of patient samples was conducted in accordance with the provisions of the Declaration of Helsinki. All patient samples were collected with priori patient consent signatures and were reviewed and approved by the Ethics Committee of State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"57"}}